Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of I-131 MIBG targeted radiotherapy for malignant neuroendocrine tumors
jRCTs041190085Phase 2Completed
- Start
- Nov 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane I-131 in apudoma (NET). Primary endpoint: Assessment of anti-tumor effects with catecholamines in blood and urine. Started Nov 2019; status: completed.
02
Drugs
Iobenguane I-131
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on jRCTs041190085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190085.